Journal of Clinical Oncology, Vol 19, Issue 5
(March), 2001: 1421-1429
© 2001 American Society for Clinical Oncology
Pharmacokinetic Evaluation of N-[2-(Dimethylamino)Ethyl]Acridine-4-Carboxamide in Patients by Positron Emission Tomography
By Azeem Saleem,
Robert J. Harte,
Julian C. Matthews,
Safiye Osman,
Frank Brady,
Sajinder K. Luthra,
Gavin D. Brown,
Norman Bleehen,
Tom Connors,
Terry Jones,
Pat M. Price,
Eric O. Aboagye
From the Cancer Research Campaign Positron Emission Tomography Oncology Group, Methodology Group, and Chemistry and Engineering Group, Division of Cancer Medicine, Imperial College School of Medicine, Medical Research Council Cyclotron Unit, Hammersmith Hospital; School of Pharmacy, University of London, London; and Department of Oncology, Addenbrookes Hospital, Cambridge, United Kingdom.
Address reprint requests to Pat M. Price, MD, Cancer Research Campaign Positron Emission Tomography Oncology Group, Division of Cancer Medicine, Imperial College School of Medicine, Medical Research Council Cyclotron Unit, Hammersmith Hospital, Du Cane Rd, London W12 0NN, United Kingdom; email: anne.mason{at}christie-tr.nwest.nhs.uk © 2001 by American Society of Clinical Oncology. 0732-183X/01/05-2
PURPOSE: To evaluate tumor, normal tissue, and plasma pharmacokinetics of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA). The study aimed to determine the pharmacokinetics of carbon-11–labeled DACA ([11C]DACA) and evaluate the effect of pharmacologic doses of DACA on radiotracer kinetics.
PATIENTS AND METHODS: [11C]DACA (at 1/1,000 phase I starting dose) was administered to 24 patients with advanced cancer (pre–phase I) or during a phase I trial of DACA in five patients. Positron emission tomography (PET) was performed to assess pharmacokinetics and tumor blood flow. Plasma samples were analyzed for metabolite profile of [11C]DACA.
RESULTS: There was rapid systemic clearance of [11C]DACA over 60 minutes (1.57 and 1.46 L·min-1·m-2in pre–phase I and phase I studies, respectively) with the production of several radiolabeled plasma metabolites. Tumor, brain, myocardium, vertebra, spleen, liver, lung, and kidneys showed appreciable uptake of 11C radioactivity. The area under the time-versus-radioactivity curves (AUC) showed the highest variability in tumors. Of interest to potential toxicity, maximum radiotracer concentrations (Cmax) in brain and vertebra were low (0.67 and 0.54 m2·mL-1, respectively) compared with other tissues. A moderate but significant correlation was observed for tumor blood flow with AUC (r = 0.76; P = .02) and standardized uptake value (SUV) at 55 minutes (r = 0.79; P = .01). A decrease in myocardial AUC ( P = .03) and splenic and myocardial SUV ( P = .01 and .004, respectively) was seen in phase I studies. Significantly higher AUC, SUV, and Cmax were observed in tumors in phase I studies.
CONCLUSION: The distribution of [11C]DACA and its radiolabeled metabolites was observed in a variety of tumors and normal tissues. In the presence of unlabeled DACA, pharmacokinetics were altered in myocardium, spleen, and tumors. These data have implications for predicting activity and toxicity of DACA and support the use of PET early in drug development.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Saleem and P. M. Price
Early Tumor Drug Pharmacokinetics Is Influenced by Tumor Perfusion but not Plasma Drug Exposure
Clin. Cancer Res.,
December 15, 2008;
14(24):
8184 - 8190.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Boss, R. V. Olmos, M. Sinaasappel, J. H. Beijnen, and J. H. M. Schellens
Application of PET/CT in the Development of Novel Anticancer Drugs
Oncologist,
January 1, 2008;
13(1):
25 - 38.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Kimmelman
Ethics at Phase 0: Clarifying the Issues
J. Law Med. Ethics,
December 1, 2007;
35(4):
727 - 733.
[PDF]
|
|
|
|
|
|
|
W.-A. Hsueh, A. L. Kesner, A. Gangloff, M. D. Pegram, M. Beryt, J. Czernin, M. E. Phelps, and D. H.S. Silverman
Predicting Chemotherapy Response to Paclitaxel with 18F-Fluoropaclitaxel and PET
J. Nucl. Med.,
December 1, 2006;
47(12):
1995 - 1999.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Workman, E. O. Aboagye, Y.-L. Chung, J. R. Griffiths, R. Hart, M. O. Leach, R. J. Maxwell, P. M. J. McSheehy, P. M. Price, and J. Zweit
Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies.
J Natl Cancer Inst,
May 3, 2006;
98(9):
580 - 598.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Saleem
Potential of PET in oncology and radiotherapy
Br. J. Radiol.,
November 1, 2005;
Supplement_28(1):
6 - 16.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Saleem, G. D. Brown, F. Brady, E. O. Aboagye, S. Osman, S. K. Luthra, A. S. O. Ranicar, C. S. Brock, M. F. G. Stevens, E. Newlands, et al.
Metabolic Activation of Temozolomide Measured in Vivo Using Positron Emission Tomography
Cancer Res.,
May 15, 2003;
63(10):
2409 - 2415.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Wells, E. Aboagye, R. N. Gunn, S. Osman, A. V. Boddy, G. A. Taylor, I. Rafi, A. N. Hughes, A. H. Calvert, P. M. Price, et al.
2-[11C]Thymidine Positron Emission Tomography as an Indicator of Thymidylate Synthase Inhibition in Patients Treated With AG337
J Natl Cancer Inst,
May 7, 2003;
95(9):
675 - 682.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D.J. Propper, J. de Bono, A. Saleem, S. Ellard, E. Flanagan, J. Paul, T.S. Ganesan, D.C. Talbot, E.O. Aboagye, P. Price, et al.
Use of Positron Emission Tomography in Pharmacokinetic Studies to Investigate Therapeutic Advantage in a Phase I Study of 120-Hour Intravenous Infusion XR5000
J. Clin. Oncol.,
January 15, 2003;
21(2):
203 - 210.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
